Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks if kidney disease affects cancer drug safety

NCT ID NCT04953897

Recruiting now Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. The main goal is to measure drug levels and check safety over about 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
oral decitabine and cedazuridine (ASTX727)
What this could lead to
If successful, this study could show that ASTX727 is safe and works similarly in patients with severe kidney problems, potentially expanding treatment access for AML and MDS.
What could go wrong
This is a very early (Phase 1b), small study with only 18 participants. It focuses on drug levels and safety, not on curing the disease. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid cell neoplasm myelodysplastic syndrome Myelodysplastic Syndromes neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • BIO1

    WITHDRAWN

    Vilnius, Lithuania

  • Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.

    RECRUITING

    Wroclaw, 51-162, Poland

  • Complex Oncology Center - Plovdiv - Base II

    WITHDRAWN

    Plovdiv, Bulgaria

  • Erebuni Medical Center

    RECRUITING

    Yerevan, Armenia

  • Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders)

    RECRUITING

    Yerevan, Armenia

  • Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology)

    RECRUITING

    Yerevan, Armenia

  • Hospital Clínico Universitario Virgen de la Arrixaca (Hematology Dept)

    RECRUITING

    Murcia, 30120, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca (Solid Tumor Dept)

    RECRUITING

    Murcia, Spain

  • Hospital Universitari Arnau de Vilanova

    RECRUITING

    Lleida, Spain

  • Hospital Universitari Dexeus - Grupo Quirónsalud

    WITHDRAWN

    Barcelona, Spain

  • Hospital Universitari i Politècnic La Fe

    TERMINATED

    Valencia, Spain

  • Hospital Universitario 12 de Octubre

    WITHDRAWN

    Madrid, Spain

  • Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu

    RECRUITING

    Bucharest, 22328, Romania

  • Institutul Oncologic Prof. Dr. Ion Chiricuta

    RECRUITING

    Cluj-Napoca, 400015, Romania

  • MD Anderson

    RECRUITING

    Houston, Texas, 77030, United States

  • National Center of Oncology Named After V.A. Fanarjyan

    RECRUITING

    Yerevan, Armenia

  • START Barcelona - Hospital HM Nou Delfos

    RECRUITING

    Barcelona, 8023, Spain

  • START Madrid - CIOCC - HM Sanchinarro

    RECRUITING

    Madrid, 28050, Spain

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, 28040, Spain

  • START Rioja - Hospital de San Pedro

    RECRUITING

    La Rioja, 26006, Spain

  • Summit Clinical Research s.r.o

    RECRUITING

    Bratislava, 831 01, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.